Lung Transplantation for Lymphangioleiomyomatosis in Japan
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Lung transplantation has been established as the definitive treatment option for patients with advanced lymphangioleiomyomatosis (LAM). However, the prognosis after registration and the circumstances of lung transplantation with sirolimus therapy have never been reported. METHODS: In this national survey, we analyzed data from 98 LAM patients registered for lung transplantation in the Japan Organ Transplantation Network. RESULTS: Transplantation was performed in 57 patients as of March 2014. Survival rate was 86.7% at 1 year, 82.5% at 3 years, 73.7% at 5 years, and 73.7% at 10 years. Of the 98 patients, 21 had an inactive status and received sirolimus more frequently than those with an active history (67% vs. 5%, p<0.001). Nine of twelve patients who remained inactive as of March 2014 initiated sirolimus before or while on a waiting list, and remained on sirolimus thereafter. Although the statistical analysis showed no statistically significant difference, the survival rate after registration tended to be better for lung transplant recipients than for those who awaited transplantation (p = 0.053). CONCLUSIONS: Lung transplantation is a satisfactory therapeutic option for advanced LAM, but the circumstances for pre-transplantation LAM patients are likely to alter with the use of sirolimus.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fewer patients with LAM have required lung transplant since the standardized use of mTOR inhibitors as treatment, but it remains an indication for those with severely abnormal lung function (FEV1 < 30%), exertional dyspnea (NYHA class III or IV), or hypoxemia at rest.(303–306, 308–315)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [303]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While disease recurrence does occur post-transplant, it does not appear to limit survival.(303, 304, 309, 311, 316–318)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [303]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although lymphangioleiomyomatosis (LAM) is not a common indication for transplantation, it has better outcomes after transplantation than other diseases.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [63]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the current consensus is that they should be used until transplantation is considered, and the patient should be thoroughly educated about the risks involved [63-65].”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [63]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Even though it is rare for LAM patients to require transplantation owing to the use of the mechanistic target of rapamycin (mTOR) inhibitors”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [63]
Experimental — accuracy not yet measured
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guidelines for the diagnosis and treatment of pulmonary hypertension
(2009) · European Respiratory Journal · doi:10.1183/09031936.00139009 · Cited by 1,300
Regulation of the mTOR Complex 1 Pathway by Nutrients, Growth Factors, and Stress
Sengupta, S., Peterson, T. R., & Sabatini, D. M. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.026 · Cited by 1,241
Efficacy and safety of sirolimus in lymphangioleiomyomatosis
McCormack, F. X., Inoue, Y., Moss, J., Singer, L. G., Strange, C., Nakata, K., Barker, A. F., Chapman, J. T., Brantly, M. L., Stocks, J. M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1100391 · Cited by 1,099
Self-citationKwiatkowski, D. J. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.5.525 · Cited by 667
Carsillo, T., Astrinidis, A., & Henske, E. P. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.11.6085 · Cited by 646
European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis
Johnson, S. R., Cordier, J. F., Lazor, R., Cottin, V., Costabel, U., Harari, S., Reynaud-Gaubert, M., Boehler, A., Brauner, M., Popper, H., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00076209 · Cited by 590 · cited 1×
“Lymphangioleiomyomatosis (LAM) is a rare neoplastic disease, characterized by the proliferation of abnormal smooth muscle-like cells (LAM cells), which lead to cystic destruction of the lungs, chylous effusions and the formation of lymphangioleiomyomas [1].”
BackgroundYusen, R. D., Christie, J. D., Edwards, L. B., Kucheryavaya, A. Y., Benden, C., Dipchand, A. I., Dobbels, F., Kirk, R., Lund, L. H., Rahmel, A. O., et al. (2013) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2013.08.007 · Cited by 506
Tuberin Regulates p70 S6 Kinase Activation and Ribosomal Protein S6 Phosphorylation
Goncharova, E. A., Goncharov, D. A., Eszterhas, A., Hunter, D. S., Glassberg, M. K., Yeung, R. S., Walker, C. L., Noonan, D., Kwiatkowski, D. J., Chou, M. M., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202678200 · Cited by 425
Guidelines for the diagnosis and treatment of pulmonary hypertension
Galie, N., Hoeper, M. M., Humbert, M., Torbicki, A., Vachiery, J.-L., Barbera, J. A., Beghetti, M., Corris, P., Gaine, S., Gibbs, J. S., et al. (2012) · Revista Portuguesa de Cardiologia (English Edition) · doi:10.1016/j.repce.2011.10.006 · Cited by 257
Lung Transplantation for Lymphangioleiomyomatosis
Boehler, A., Speich, R., Russi, E. W., & Weder, W. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610243351704 · Cited by 217
Research works printed but not linked: 1
- J Groetzner, 2004, Airway anastomosis complications in de novo lung transplantation with sirolimus-based immunosuppression, J Heart Lung Transplant, 23, 632, 10.1016/S1053-2498(03)00309-7 · DOI · Paper page
Cited by
Leard, L. E., Holm, A. M., Valapour, M., Glanville, A. R., Attawar, S., Aversa, M., Campos, S. V., Christon, L. M., Cypel, M., Dellgren, G., et al. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.07.005 · Cited by 821
Lymphangioleiomyomatosis: pathogenesis, clinical features, diagnosis, and management
McCarthy, C., Gupta, N., Johnson, S. R., Yu, J. J., & McCormack, F. X. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00228-9 · Cited by 209
Lymphangioleiomyomatosis: a clinical review
O'Mahony, A. M., Lynn, E., Murphy, D. J., Fabre, A., & McCarthy, C. (2020) · Breathe · doi:10.1183/20734735.0007-2020 · Cited by 56
Khawar, M. U., Yazdani, D., Zhu, Z., Jandarov, R., Dilling, D. F., & Gupta, N. (2019) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2019.06.015 · Cited by 45
Spontaneous pneumothorax in diffuse cystic lung diseases
Cooley, J. C., Lee, G., & Gupta, N. (2017) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000391 · Cited by 43
Metadata
- Authors
- Ando, K., Okada, Y., Akiba, M., Kondo, T., Kawamura, T., Okumura, M., Chen, F., Date, H., Shiraishi, T., Iwasaki, A., Yamasaki, N., Nagayasu, T., Chida, M., Inoue, Y., Hirai, T., Seyama, K., Mishima, M., & Respiratory Failure Research Group of the Japanese Ministry of Health, L.
- Affiliations
- Juntendo University (JP)
- Tohoku University (JP)
- The University of Osaka (JP)
- Kyoto University (JP)
- Fukuoka University (JP)
- Nagasaki University (JP)
- Dokkyo University (JP)
- Ministry of Health Labour and Welfare (JP)
- Corresponding author
- Seyama, Kuniaki
- ORCID
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-01-15
- Volume
- 11
- Issue
- 1
- Pages
- e0146749
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4714890
- OpenAlex
- W2247267173
- Cited by
- 37
- References
- 30
- Citations by year
- 2025: 3 · 2024: 1 · 2023: 5 · 2022: 8 · 2021: 6 · 2020: 3 · 2019: 2 · 2018: 4 · 2017: 5
- FWCI
- 2.95
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Kyoto University Research Information Repository (Kyoto University) (submittedVersion, cc-by)
- Funders
- Nihon University
- Keio University
- Ministry of Health, Labour and Welfare
- University of Tokyo
- Hokkaido University
- Chiba University
- Tokyo Women's Medical University
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Tuberous Sclerosis Complex Research
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Medical Imaging and Pathology Studies
- Keywords
- lymphangioleiomyomatosis, lung transplantation, rapamycin, transplant recipient survival, transplant waiting list
- MeSH terms
- Adult, Anti-Bacterial Agents, Female, Humans, Japan, Lung Neoplasms, Male, Middle Aged, Retrospective Studies, Survival Rate, Lung Transplantation, Lymphangioleiomyomatosis, Sirolimus, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lung Transplantation for Lymphangioleiomyomatosis in Japan. https://app.cochat.ai/papers/10.1371/journal.pone.0146749
- The paper
- Ando, K., Okada, Y., Akiba, M., Kondo, T., Kawamura, T., Okumura, M., Chen, F., Date, H., Shiraishi, T., Iwasaki, A., Yamasaki, N., Nagayasu, T., Chida, M., Inoue, Y., Hirai, T., Seyama, K., Mishima, M., & Respiratory Failure Research Group of the Japanese Ministry of Health, L. (2016). Lung Transplantation for Lymphangioleiomyomatosis in Japan. PLOS ONE. https://doi.org/10.1371/journal.pone.0146749
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.